HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Curtis G. Tribble Thomas S. Maxey John A. Kern Irving L. Kron Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reece, T. B. Articles by Kron, I. L. Search for Related Content PubMed PubMed Citation Articles by Reece, T. B. Articles by Kron, I. L. Related Collections Lung - transplantation

Ann Thorac Surg 2005;79:1189-1195
© 2005 The Society of Thoracic Surgeons

---

Original articles: General thoracic

Adenosine A_2A Receptor Agonist Improves Cardiac Dysfunction From Pulmonary Ischemia-Reperfusion Injury

^a Department of Surgery, University of Virginia Health System, Charlottesville, Virginia
^b Department of Cardiovascular Research Center, University of Virginia Health System, Charlottesville, Virginia

Accepted for publication September 21, 2004.

^_* Address reprint requests to Dr Reece, University of Virginia, Department of Surgery, PO Box 801359, Charlottesville, VA 22908 (E-mail: tbr5q{at}virginia.edu).

BACKGROUND: Ischemia-reperfusion (IR) injury negatively impacts patient outcome in lung transplantation. Clinically, we observed that lung transplant patients with ischemia-reperfusion injury tend to have cardiac dysfunction. Previous studies have shown that ATL-146e (4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester), a selective adenosine A_2A receptor agonist, reduces lung inflammation after ischemia-reperfusion. We hypothesized that pulmonary ischemia-reperfusion causes secondary heart dysfunction and ATL-146e will improve this dysfunction.

METHODS: We utilized an in vivo rabbit lung ischemia-reperfusion model. The Sham group underwent 120 minutes single lung ventilation. The IR and ATL groups underwent 90 minutes right lung ischemia with 30 minutes right lung reperfusion. The ATL-146e was given intravenously to the ATL group during reperfusion. Cardiac output and arterial blood gases were monitored, and neutrophil sequestration was measured by myeloperoxidase activity.

RESULTS: Upon reperfusion, cardiac output (mL/min) significantly dropped in the IR and ATL groups. By 15 minutes reperfusion, cardiac output in the ATL group improved significantly over the IR group and remained significant thereafter. Lung myeloperoxidase activity was significantly reduced by ATL-146e. Although never hypoxemic, arterial oxygenation was lower in the IR and ATL groups while central venous pressures and mean arterial pressures were similar among groups. A separate experiment demonstrated that reperfusion with the antioxidant N-(2-mercaptopropionyl)glycine prevented cardiac dysfunction.

CONCLUSIONS: Pulmonary ischemia-reperfusion causes cardiac dysfunction independent of preload, afterload, and oxygenation. The ATL-146e improves this dysfunction presumably by the antiinflammatory effects of adenosine A_2A receptor activation on neutrophils. One likely mechanism involves the release of oxidants from the ischemic lung upon reperfusion, which has immediate negative effects on the heart.

This article has been cited by other articles:

				J. Reutershan, R. E. Cagnina, D. Chang, J. Linden, and K. Ley Therapeutic Anti-Inflammatory Effects of Myeloid Cell Adenosine Receptor A2a Stimulation in Lipopolysaccharide-Induced Lung Injury J. Immunol., July 15, 2007; 179(2): 1254 - 1263. [Abstract] [Full Text] [PDF]

				T. B. Reece, D. O. Okonkwo, P. I. Ellman, T. S. Maxey, C. Tache-Leon, P. S. Warren, J. J. Laurent, J. Linden, I. L. Kron, C. G. Tribble, et al. Comparison of Systemic and Retrograde Delivery of Adenosine A2A Agonist for Attenuation of Spinal Cord Injury After Thoracic Aortic Cross-Clamping Ann. Thorac. Surg., March 1, 2006; 81(3): 902 - 909. [Abstract] [Full Text] [PDF]